Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO(BMY) · Entity 1662 | Director | March 31, 2006 | April 04, 2006 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | April 30, 2025 | May 03, 2025 |
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director | July 22, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 31, 2006 · Filed April 04, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 22,932.28 |
Reported balance
After 2006-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2006-03-31 · Grant · Acquired 203.63 · Balance 22,932.28 F1: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director.
Emergent BioSolutions Inc.
Report date April 30, 2025 · Filed May 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 139,098 |
Reported balance
After 2025-04-30 transaction · row 1
1 source rowRow 1 · 2025-04-30 · Grant · Acquired 34,403 · Balance 139,098 F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.45 · Expires 2032-04-29 | Direct | 41,572 |
Reported balance
After 2025-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-30 · Grant · Acquired 15,824 · Balance 41,572 F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
UNITED THERAPEUTICS Corp
Report date July 22, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $527.07 · Expires 2033-07-22 | Direct | 2,380 |
Reported balance
After 2026-07-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-22 · Grant · Acquired 2,380 · Balance 2,380 F3: Annual non-employee director award. F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. |
| Common StockSEC Table I · non-derivative | Direct | 2,983 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,983 F1: Total has been updated to correct a clerical error which caused the reporting person's indirect holding of common stock (by trust) to be underreported by 590 shares in the Form 4 filed on July 13, 2026 by the reporting person. These shares are in addition to the 2,903 shares held directly, as reported in the Form 4 filed on July 13, 2026. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 1,457 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,457 F2: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power. |
Filing footnotes · ownership attribution and instrument terms
F1: Total has been updated to correct a clerical error which caused the reporting person's indirect holding of common stock (by trust) to be underreported by 590 shares in the Form 4 filed on July 13, 2026 by the reporting person. These shares are in addition to the 2,903 shares held directly, as reported in the Form 4 filed on July 13, 2026.
F2: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power.
F3: Annual non-employee director award.
F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2023 Filed Jul 17, 2023 10:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 4,560 | $0.00 Strike: $229.81 | $0.00 |
DisclosureSEC source: 0001415889-23-011152 · form4-07172023_060711.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,560 Underlying: Common Stock · 4,560 shares Expires 2033-07-13 F1 · shares: Annual non-employee director award. F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 07, 2023 Filed Jul 7, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Unit · Derivative | 880 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010952 · form4-07072023_040717.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 880 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares received upon vesting of restricted stock units on July 7, 2023. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · kind: Shares received upon vesting of restricted stock units on July 7, 2023. Restricted stock units converted on a one-for-one basis into shares of common stock. F2 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 07, 2023 Filed Jul 7, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 880 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010952 · form4-07072023_040717.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received upon vesting of restricted stock units on July 7, 2023. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · price: Shares received upon vesting of restricted stock units on July 7, 2023. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| May 25, 2023 Filed May 30, 2023 23:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 33,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000107 · wk-form4_1685488014.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,265 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan, as amended and restated. These restricted stock units vest in one installment beginning on the day prior to the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 700 | $0.00 Strike: $132.30 | $0.00 |
DisclosureSEC source: 0001415889-23-003824 · form4-03022023_040329.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 700 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 700 | $245.10 | $171,570.00 |
DisclosureSEC source: 0001415889-23-003824 · form4-03022023_040329.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,180 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 700 | $132.30 | $92,610.00 |
DisclosureSEC source: 0001415889-23-003824 · form4-03022023_040329.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 700 | $0.00 Strike: $132.30 | $0.00 |
DisclosureSEC source: 0001415889-23-001809 · form4-02022023_040201.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 Underlying: Common Stock · 700 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 700 | $261.33 | $182,931.00 |
DisclosureSEC source: 0001415889-23-001809 · form4-02022023_040201.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,180 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 700 | $132.30 | $92,610.00 |
DisclosureSEC source: 0001415889-23-001809 · form4-02022023_040201.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 22:20 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 700 | $0.00 Strike: $132.30 | $0.00 |
DisclosureSEC source: 0001415889-23-000105 · form4-01032023_100100.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common Stock · 700 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 22:20 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 700 | $276.26 | $193,382.00 |
DisclosureSEC source: 0001415889-23-000105 · form4-01032023_100100.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,180 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 22:20 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 700 | $132.30 | $92,610.00 |
DisclosureSEC source: 0001415889-23-000105 · form4-01032023_100100.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 01, 2022 Filed Dec 1, 2022 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 700 | $0.00 Strike: $132.30 | $0.00 |
DisclosureSEC source: 0001415889-22-011882 · form4-12012022_041214.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 700 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 01, 2022 Filed Dec 1, 2022 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 700 | $279.89 | $195,923.00 |
DisclosureSEC source: 0001415889-22-011882 · form4-12012022_041214.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,180 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 01, 2022 Filed Dec 1, 2022 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 700 | $132.30 | $92,610.00 |
DisclosureSEC source: 0001415889-22-011882 · form4-12012022_041214.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 700 | $0.00 Strike: $132.30 | $0.00 |
DisclosureSEC source: 0001415889-22-010999 · form4-11022022_041101.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Underlying: Common Stock · 700 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 700 | $230.28 | $161,196.00 |
DisclosureSEC source: 0001415889-22-010999 · form4-11022022_041101.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,180 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 700 | $132.30 | $92,610.00 |
DisclosureSEC source: 0001415889-22-010999 · form4-11022022_041101.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:34 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 710 | $0.00 Strike: $132.30 | $0.00 |
DisclosureSEC source: 0001415889-22-010072 · form4-10032022_041009.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 710 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:34 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 710 | $211.56 | $150,207.60 |
DisclosureSEC source: 0001415889-22-010072 · form4-10032022_041009.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,180 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:34 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 710 | $132.30 | $93,933.00 |
DisclosureSEC source: 0001415889-22-010072 · form4-10032022_041009.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 4,910 | $0.00 Strike: $101.80 | $0.00 |
DisclosureSEC source: 0001415889-22-009375 · form4-09062022_040906.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,910 shares Expires 2026-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,910 | $225.98 | $1,109,550.02 |
DisclosureSEC source: 0001415889-22-009375 · form4-09062022_040906.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,180 Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 4,910 | $101.80 | $499,838.00 |
DisclosureSEC source: 0001415889-22-009375 · form4-09062022_040906.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2022 Filed Jul 8, 2022 21:42 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Unit · Derivative | 3,230 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007602 · form4-07082022_020747.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,230 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 08, 2022 Filed Jul 8, 2022 21:42 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007602 · form4-07082022_020747.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock Read SEC document |
| July 08, 2022 Filed Jul 11, 2022 20:30 UTC Amendment | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Unit · Derivative | 1,080 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007628 · form4a-07112022_040717.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,080 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F1 · shares: This amendment corrects an overstatement of the number of restricted stock units that vested on July 8, 2022, and the number of resulting shares of common stock received by the reporting person. In both cases, the original number reported (3,230 restricted stock units / shares of common stock) has been corrected (1,080 restricted stock units / shares of common stock). F4 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F4 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 08, 2022 Filed Jul 11, 2022 20:30 UTC Amendment | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007628 · form4a-07112022_040717.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This amendment corrects an overstatement of the number of restricted stock units that vested on July 8, 2022, and the number of resulting shares of common stock received by the reporting person. In both cases, the original number reported (3,230 restricted stock units / shares of common stock) has been corrected (1,080 restricted stock units / shares of common stock). F2 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:42 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 2,490 | $0.00 Strike: $240.20 | $0.00 |
DisclosureSEC source: 0001415889-22-007602 · form4-07082022_020747.xml · derivative · entry 4 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,490 Underlying: Common Stock · 2,490 shares Expires 2032-07-07 F4 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:42 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Unit · Derivative | 880 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007602 · form4-07082022_020747.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880 Underlying: Common Stock · 880 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| May 26, 2022 Filed May 26, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,310 | $0.00 Strike: $76.36 | $0.00 |
DisclosureSEC source: 0001415889-22-005696 · form4-05262022_040510.xml · derivative · entry 6 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,310 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2022 Filed May 26, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,345 | $226.74 | $304,963.01 |
DisclosureSEC source: 0001415889-22-005696 · form4-05262022_040510.xml · nonDerivative · entry 5 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,100 F4 · price: This transaction was executed in multiple trades at prices ranging from $226.50 to $226.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 26, 2022 Filed May 26, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,500 | $226.04 | $339,062.85 |
DisclosureSEC source: 0001415889-22-005696 · form4-05262022_040510.xml · nonDerivative · entry 4 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,445 F3 · price: This transaction was executed in multiple trades at prices ranging from $225.48 to $226.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 26, 2022 Filed May 26, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,766 | $224.38 | $396,249.96 |
DisclosureSEC source: 0001415889-22-005696 · form4-05262022_040510.xml · nonDerivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,945 F2 · price: This transaction was executed in multiple trades at prices ranging from $224.00 to $224.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 26, 2022 Filed May 26, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,699 | $223.37 | $379,505.63 |
DisclosureSEC source: 0001415889-22-005696 · form4-05262022_040510.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,711 F1 · price: This transaction was executed in multiple trades at prices ranging from $222.94 to $223.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 26, 2022 Filed May 26, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,310 | $76.36 | $481,831.60 |
DisclosureSEC source: 0001415889-22-005696 · form4-05262022_040510.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2022 Filed May 31, 2022 20:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000089 · wf-form4_165402808228714.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,418 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 21:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 1,080 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-021766 · form4.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,080 Underlying: Common Stock · 1,080 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · shares: Annual non-employee director grant of restricted stock units, which are awarded each year on the date of the first board meeting following the issuer's Annual Meeting of Shareholders. F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F2 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 21:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 3,230 | $183.98 Strike: $183.98 | $594,255.40 |
DisclosureSEC source: 0001127602-21-021766 · form4.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,230 Underlying: Common Stock · 3,230 shares Expires 2031-07-08 F1 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the first board meeting following the issuer's Annual Meeting of Shareholders. F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2021 Filed Jun 28, 2021 22:17 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Units · Derivative | 1,680 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-21-020758 · form4.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F1 · price: Shares received upon vesting of restricted stock units on June 26, 2021. Restricted stock units converted on a one-for-one basis into shares of common stock. F3 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| June 26, 2021 Filed Jun 28, 2021 22:17 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020758 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares received upon vesting of restricted stock units on June 26, 2021. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| May 20, 2021 Filed May 24, 2021 21:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000097 · wf-form4_162189081830999.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,972 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:34 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 15,000 | $0.00 Strike: $88.03 | $0.00 |
DisclosureSEC source: 0001127602-21-016406 · form4.xml · derivative · entry 6 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:34 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 15,000 | $0.00 Strike: $63.90 | $0.00 |
DisclosureSEC source: 0001127602-21-016406 · form4.xml · derivative · entry 5 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:34 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 15,000 | $194.30 | $2,914,500.00 |
DisclosureSEC source: 0001127602-21-016406 · form4.xml · nonDerivative · entry 4 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,420 F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:34 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 15,000 | $88.03 | $1,320,450.00 |
DisclosureSEC source: 0001127602-21-016406 · form4.xml · nonDerivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:34 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 15,000 | $194.30 | $2,914,500.00 |
DisclosureSEC source: 0001127602-21-016406 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,420 F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:34 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 15,000 | $63.90 | $958,500.00 |
DisclosureSEC source: 0001127602-21-016406 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| May 10, 2021 Filed May 11, 2021 20:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 10,305 | $0.00 Strike: $18.64 | $0.00 |
DisclosureSEC source: 0001367644-21-000075 · wf-form4_162076428587593.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,305 shares Expires 2021-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option vested in three equal installments in May 2015, May 2016 and May 2017. Each option represents the right of the reporting person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.